BCAB (bioatla.com) Company Cash on Hand

Graphic logo of BioAtla, Inc. (BCAB)

The current cash position of BioAtla, Inc. (BCAB) allows for an assessment of the business's liquidity, where the 0.00 mark indicates the current state. Risks are associated with potential drug toxicity and dependence on major partners. Demand for cancer treatment renders the company independent of macroeconomic factors. Meanwhile, research and development capacities and contract manufacturing are fully prepared to scale antibody production.

BCAB - BioAtla, Inc. Company Cash Balance over the range 07/04/2022 - 09/06/2026

Financial and market metric breakdowns for BioAtla, Inc. (BCAB)

- current price and projected stock value:
- business market valuation indicators:
Comprehensive company analysis:BCAB BioAtla Inc
Signature product of BioAtla Corp

The high burn rate of BioAtla, Inc. (BCAB) due to clinical trial risks makes liquidity control critical for business survival. This metric measures the volume of available cash, allowing for an assessment of management's financial discipline and the actual speed of resource consumption without market noise. Analyzing the free cash flow chart helps investors determine the company's remaining operational runway before a new funding round becomes necessary.